



[Go to Product page](#)

Datasheet for ABIN7200654

Recombinant anti-EGFR (Cetuximab Biosimilar) antibody

Overview

Quantity:	1 mg
Target:	EGFR (Cetuximab Biosimilar)
Reactivity:	Human
Host:	Mouse
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This EGFR (Cetuximab Biosimilar) antibody is un-conjugated
Application:	In vivo Studies (in vivo), Flow Cytometry (FACS)

Product Details

Purpose:	Cetuximab Biosimilar, Human EGFR Monoclonal Antibody
Immunogen:	The monoclonal antibody cetuximab biosimilar was produced in the cetuximab biosimilar CHO stable cell line.
Clone:	C225
Isotype:	IgG1 kappa
Specificity:	The monoclonal antibody cetuximab biosimilar specifically binds to the human EGFR.
Characteristics:	Recombinant Chimeric IgG1 Monoclonal Antibody.
Purification:	Protein A affinity column
Purity:	> 95% by SDS-PAGE under reducing conditions and HPLC.
Sterility:	0.2 µm filtered

Product Details

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Target Details

Target: EGFR (Cetuximab Biosimilar)

Abstract: [EGFR \(Cetuximab Biosimilar\) Products](#)

Target Type: Biosimilar

Background: Cetuximab, a chimeric (mouse/human) anti-EGFR monoclonal antibody, is an EGFR inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab binds to EGFR and turns off the uncontrolled growth in cancers with EGFR mutations.

Cetuximab can be used for treatment of KRAS wild type colon cancer but has little or no effect in colorectal tumors harboring a KRAS mutation. Before treatment using Erbitux, it is better to do a diagnosis using the real time PCR companion diagnostic test for KRAS, the theascreen KRAS test.

There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1; HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, EGFR (epidermal growth factor receptor) located on cell surface sends a signal down the MAPK pathway that includes another protein, KRAS (also spelled K-ras). Mutations affecting EGFR and/or KRAS expression or activity could result in cancer. The mutated KRAS continuously sends a growth signal to the downstream pathway, leading to uncontrollable cell division, even if EGFR has been blocked.

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by cetuximab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Handling

Buffer:	PBS, pH 7.4, no stabilizers or preservatives.
Preservative:	Without preservative
Handling Advice:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Storage:	-20 °C
Storage Comment:	12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Expiry Date:	12 months